MATHUR N, DAWES C and MORAN PM, 2019. Olfactory Threshold Selectively Predicts Positive Psychometric Schizotypy Schizophrenia Research.
C O'TUATHAIGH, N MATHUR, M O'CALLAGHAN, M LAI, R HARVEY, J WADDINGTON, B PICKARD, D WATSON and PM MORAN, 2017. Specialised information processing deficits and distinct metabolomic profiles following TM-domain disruption of NRG1 Schizophrenia Bulletin. OYEGBAMI O, COLLINS H, PARDON MC, EBLING F, HEERY DM and MORAN PM, 2017. Abnormal clock gene expression and locomotor activity rhythms in two month-old female APPSwe/PS1dE9 mice. Current Alzheimer Research. 14(8), 850-860 FULTON J, MAZUMDER B, WHITCHURCH J, MONTEIRO C, COLLINS H, CHAN C, CLEMENTE M, HERNANDEZ QUILES M, STEWART E, AMOAKU W, MORAN PM, MONGAN N, PERSSON J, ALI S and HEERY DM, 2017. Heterodimers of Photoreceptor-Specific Nuclear Receptor (NR2E3) and Peroxisome Proliferator-Activated Receptor (PPARγ) are Disrupted by Retinal Disease-Associated Mutations. Cell Death and Disease. 8, e2677 BAILEY SJ, NEILL JC and MORAN PM, 2017. Pharmacology of cognition: a panacea for neuropsychiatric disease? British Journal of Pharmacology.
RAFTER M, FONE KC and MORAN PM, 2016. Glutamate Pharmacological models relevant to schizophrenia and psychosis: can a receptor occupancy normalisation approach reduce the gap between animal and human experiments ?. In: MIKHAIL PLETNIKOV, ed., Modeling Psychopathogical dimensions of Schizophrenia: From molecules to Behaviour 23. Elsevier. 140-184
GRANGER K, MORAN PM, BUCKLEY M and HASELGROVE M, 2016. Enhanced latent inhibition in high schizotypy individuals Personality and Individual Differences. 91, 31-39 MORAN PM, STOKES J, MARR J, BOCK G, DESBONNET L, WADDINGTON JL and O'TUATHAIGH CMP, 2016. Gene-environment interactions in schizophrenia: evidence from genetic mouse models Neural Plasticity. 2016, Article ID 2173748
PM MORAN, CM O'TUATHAIGH, F PAPALEO and JL WADDINGTON, 2014. Dopaminergic Function in Relation to Genes Associated with Risk for Schizophrenia: Translational Mutant Mouse Models. In: M DIANA, G DICHIARA and P SPANO, eds., Progress in Brain Research : Dopamine 1. 211. Elsevier. 79-112
O'CALLAGHAN MJ, BAY-RICHTER C, O'TUATHAIGH CM, HEERY DM, WADDINGTON JL and MORAN PM, 2014. Potentiation of latent inhibition by haloperidol and clozapine is attenuated in Dopamine D2 receptor (Drd-2) deficient mice: Do antipsychotics influence learning to ignore irrelevant stimuli via both D2 and non-D2 mechanisms? Journal of Psychopharmacology. 28(10), 973-977
MORAN, P.M. and ROUSE, J.L., 2013. Integrative theories of schizophrenia and learning: a historical perspective. In: HASELGROVE, M. and HOGARTH, L., eds., Clinical applications of learning theory Psychology Press.
MCINTOSH, A.L., BALLARD, T.M., STEWARD, L.J., MORAN, P.M. and FONE, K.C.F., 2013. The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats Psychopharmacology. 228(1), 31-42 BAY-RICHTER, C., O'CALLAGHAN, M.J., MATHUR, N., O'TUATHAIGH, C.M.P., HEERY, D.M., FONE, K.C.F, WADDINGTON, J.L. and MORAN, P.M., 2013. D-amphetamine and antipsychotic drug effects on latent inhibition in mice lacking dopamine D2 receptors Neuropsychopharmacology. 38(8), 1512-1520 CHAN, C.M., FULTON, J., MONTIEL-DUARTE, C., COLLINS, H.M., BHARTI, N., WADELIN, F.R., MORAN, P.M., MONGAN, N.P. and HEERY, D.M., 2013. A signature motif mediating selective interactions of BCL11A with the NR2E/F subfamily of orphan nuclear receptors Nucleic Acids Research. 41(21), 9663-9679 MORAN, P.M., ROUSE, J.L., CROSS, B., CORCORAN, R. and SCHÜRMANN, M., 2012. Kamin blocking is associated with reduced medial-frontal gyrus activation: implications for prediction error abnormality in schizophrenia PLoS ONE. 7(8), e43905 O’TUATHAIGH, C.M.P., DESBONNET, L., KIRBY, B.P., MORAN, P.M. and WADDINGTON, J.L., 2011. Molecular genetic models related to schizophrenia and psychotic illness:heuristics and challenges. In: HAGAN, J.J., ed., Molecular and functional models in neuropsychiatry 7. Springer Verlag. 87-119 LE COZANNET, R., FONE, K.C.F. and MORAN, P.M., 2010. Phencyclidine (PCP) withdrawal disrupts episodic-like memory in rats:reversal by donepezil but not clozapine International Journal of Neuropsychopharmacology. 13(8), 1011-1020
CASSADAY, H.J. and MORAN, P.M., 2010. Latent inhibition and other effects from salience modulation: do they share the same neural substrates?. In: , LUBOW, R.E. and WEINER, I., eds., Latent inhibition : neuroscience applications and schizophrenia Cambridge University Press.
O'TUATHAIGH, C.M.P., KIRBY, B.P., MORAN, P.M. and WADDINGTON, J.L., 2010. Mutant mouse models: genotype-phenotype relationships to negative symptoms in schizophrenia Schizophrenia Bulletin. 36(2), 271-288 BAY-RICHTER, C., O'TUATHAIGH, C.M.P., O'SULLIVAN, G., HEERY, D.M., WADDINGTON, J.L. and MORAN, P.M., 2009. Enhanced latent inhibition in dopamine receptor- deficient mice is sex-specific for the D1 but not D2 receptor subtype: implications for antipsychotic drug action International Journal of Neuropsychopharmacology. 12(3), 403-414 MORAN, P.M., OWEN, L., CROOKES, A.E., AL-UZRI, M.M. and REVELEY, M.A., 2008. Abnormal prediction error is associated with negative and depressive symptoms in schizophrenia Progress in Neuro-Psychopharmacology and Biological Psychiatry. 32(1), 116-123 MIGO, E.M., CORBETT, K., GRAHAM, J., SMITH, S., TATE, S., MORAN, P.M. and CASSADAY, H.J., 2006. A novel test of conditioned inhibition correlates with personality measures of schizotypy and reward sensitivity Behavioural Brain Research. 168(2), 299-306
AL-UZRI, M.M., REVELEY, M.A., OWEN, L., BRUCE, J., FROST, S., MACKINTOSH, D. and MORAN, P.M., 2006. Measuring memory impairment in community-based patients with schizophrenia: case-control study British Journal of Psychiatry. 189(2), 132-136
SAADAT, K.S., ELLIOTT, J.M., GREEN, A.R. and MORAN, P.M., 2006. High-dose MDMA does not result in long-term changes in impulsivity in the rat Psychopharmacology. 188(1), 75-83 YOUNG, A. M., MORAN, P. M. and JOSEPH, M. H., 2005. The role of dopamine in conditioning and latent inhibition: What, when, where and how? Neuroscience & Biobehavioral Reviews. VOL 29(NUMBER 6), 963-976 O'TUATHAIGH,C.P. and MORAN,P.M., 2004. The effect of sulpiride on amphetamine-induced disruption of overshadowing in the rat Progress in Neuro-Psychopharmacology and Biological Psychiatry. 28(8), 1249-1253 MORAN,P.M., AL-UZRI,M.M., WATSON,J. and REVELEY,M.A., 2003. Reduced Kamin blocking in non paranoid schizophrenia: associations with schizotypy Journal of Psychiatric Research. 37(2), 155-163 O'TUATHAIGH,C.M.P., SALUM,C., YOUNG,A.M.J., PICKERING,A.D., JOSEPH,M.H. and MORAN,P.M., 2003. The effect of amphetamine on Kamin blocking and overshadowing Behavioural Pharmacology. 14(4), 315-322 MCDONALD,L.M., MORAN,P.M., VYTHELINGUM,G.N.., JOSEPH,M.H., STEPHENSON,J.D. and GRAY,J.A., 2003. Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning Psychopharmacology. 169(3-4), 321-331 MECHAN,A.O., MORAN,P.M., ELLIOTT,M.J., YOUNG,A.M., JOSEPH,M.H. and GREEN,R.A., 2002. A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field Psychopharmacology. 159(2), 167-175 MECHAN,A.O., MORAN,P.M.., ELLIOTT,M.J., YOUNG,A.M., JOSEPH,M.H. and GREEN,R.A., 2002. A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters, and their response to diazepam Psychopharmacology. 159(2), 188-195
MECHAN, ANNIS O, MORAN, PAULA M, ELLIOTT, MARTINJ, YOUNG, ANDREW J, JOSEPH, MICHAEL H and GREEN, RICHARDA, 2002. A study of the effect of a single neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA; "ecstasy") on the subsequent long-term behaviour of rats in the plus maze and open field. Psychopharmacology. 159(2), 167-75
MCDONALD, L. M., MORAN, P. M., VYTHELINGUM, G. N., JOSEPH, M. H., STEPHENSON, J. D. and GRAY, J. A., 2002. Latent inhibition is attenuated by noise and partially restored by a 5-HT~2~A receptor antagonist Behavioural Pharmacology. VOL 13(PART 8), 663-668
MECHAN, ANNIS O, MORAN, PAULA M, ELLIOTT, MARTINJ, YOUNG, ANDREW J, JOSEPH, MICHAEL H and GREEN, RICHARDA, 2002. A comparison between Dark Agouti and Sprague-Dawley rats in their behaviour on the elevated plus-maze, open-field apparatus and activity meters, and their response to diazepam. Psychopharmacology. 159(2), 188-95
JOSEPH, M H, PETERS, S L, MORAN, P M, GRIGORYAN, G A, YOUNG, A M and GRAY, J A, 2000. Modulation of latent inhibition in the rat by altered dopamine transmission in the nucleus accumbens at the time of conditioning. Neuroscience. 101(4), 921-30 MOSER, P C, HITCHCOCK, J M, LISTER, S and MORAN, P M, 2000. The pharmacology of latent inhibition as an animal model of schizophrenia. Brain research. Brain research reviews. 33(2-3), 275-307 GRAY, J A, MORAN, P M, GRIGORYAN, G, PETERS, S L, YOUNG, A M and JOSEPH, M H, 1997. Latent inhibition: the nucleus accumbens connection revisited. Behavioural Brain Research. 88(1), 27-34
MORAN,, FISCHER,, HITCHCOCK, and MOSER,, 1996. Effects of clozapine on latent inhibition in the rat. Behavioural Pharmacology. 7(1), 42-48
MOSER, P C, MORAN, P M, FRANK, R A and KEHNE, J H, 1996. Reversal of amphetamine-induced behaviours by MDL 100,907, a selective 5-HT2A antagonist. Behavioural Brain Research. 73(1-2), 163-7 MORAN, P M, HIGGINS, L S, CORDELL, B and MOSER, P C, 1995. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human beta-amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America. 92(12), 5341-5 MORAN, P M and MOSER, P C, 1992. MDL 73,147EF, a 5-HT3 antagonist, facilitates latent inhibition in the rat. Pharmacology, Biochemistry and Behavior. 42(3), 519-22
MORAN, P M, LEMAÎTRE, M H, PHILOUZE, V, REYMANN, J M, ALLAIN, H and LEONARD, B E, 1992. Reversal of learning and memory impairments following lesion of the nucleus basalis magnocellularis (NBM) by concurrent noradrenergic depletion using DSP4 in the rat. Brain Research. 595(2), 327-33